Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 24, 2008 Brian Orelli	Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell.
The Motley Fool April 22, 2009 Brian Orelli	Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away.
The Motley Fool July 24, 2008 Brian Orelli	Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth.
The Motley Fool October 24, 2007 Brian Orelli	Illumina's Illuminating Results There was stellar revenue growth, but margins and stock compensations pulled the bottom line down.
The Motley Fool February 4, 2009 Brian Orelli	43% Growth! Yee-Haw! Illumina rocks another quarter.
The Motley Fool July 22, 2009 Brian Orelli	Levering the Genome Lower revenue can't stop Illumina from turning in a good bottom line.
The Motley Fool August 6, 2008 Brian Orelli	Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out.
The Motley Fool July 25, 2007 Brian Orelli	Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row.
The Motley Fool October 28, 2009 Brian Orelli	Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably.
The Motley Fool April 24, 2008 Brian Orelli	Illumina Ignites This biochip maker is on fire.
The Motley Fool November 12, 2008 Brian Orelli	Affymetrix Gets Specific The biochip maker announces that it will acquire privately held Panomics for $73 million in cash.
The Motley Fool January 28, 2005 Karl Thiel	Affymetrix Raking in the Chips The life sciences research chip maker is enjoying green pastures in the gene business. The company announced fourth-quarter revenues and profits that handily beat consensus expectations, and then gave an upbeat view of 2005.
The Motley Fool July 28, 2010 Brian Orelli	Now There's an Illuminating Idea Helping your customers sell more of your product makes a lot of sense.
The Motley Fool April 27, 2011 Brian Orelli	Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby.
The Motley Fool January 14, 2010 Brian Orelli	$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome.
The Motley Fool August 4, 2006 Anders Bylund	Gee, Officer Krupke, That's a Lot of Stock Options! WebSideStory reports much lower earnings -- if you include stock-based compensation. Investors, this is still a growth story with plenty of opportunity ahead. And you can buy it at value prices right now.
The Motley Fool July 25, 2008 Brian Orelli	Affymetrix Astounds, in the Worst Way After taking a beating last quarter, biochip maker Affymetrix got pounded again in the second quarter, as its turnaround from the lows of 2006 fizzled out.
The Motley Fool February 6, 2008 Brian Orelli	Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward?
The Motley Fool August 19, 2011 Alexander Crawford	DNA Sequencing: The Next High-Growth Market in Biotech? We compiled a list of companies with a hand in the DNA sequencing market. Should you add these companies to your watch list?
The Motley Fool February 8, 2010 Brian Orelli	An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement.
Bio-IT World February 2007 Robert M. Frederickson	Scramble for CodeLink Customers GE Healthcare has quietly announced that it will stop production of the popular CodeLink array system in 2007. The news was not a complete surprise to some users of the system who felt the company had been backing away from the platform.
The Motley Fool August 12, 2009 Brian Orelli	The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing.
The Motley Fool November 17, 2006 Jack Uldrich	Neanderthal DNA Enlightens Investors Investors, the superb performance of 454's gene sequencing equipment on such a difficult and important project bodes well for its future prospects.
Registered Rep. October 1, 2005 John Churchill	I Gotta Get Paid According to a 2005 study, revenue at independent financial advisory firms grew by 25% on average in 2004.
The Motley Fool May 31, 2006 Jim Mueller	Too Many Options on the Menu Stock-based compensation weighs down the earnings of restaurants, of all things. Is it really necessary, though, if you are an established, profitable restaurant chain?
Chemistry World May 29, 2014 Hepeng Jia	Chinese-made DNA sequencer aims to challenge foreign dominance With an independently developed next-generation DNA sequencer, Chinese scientists are aiming to challenge the dominance of international players in the world's fastest growing genome sequencing market.
The Motley Fool April 25, 2008 Brian Orelli	Affymetrix Learns About Inertia Slower sales of its older chips drag down growth.
The Motley Fool August 18, 2010 Luke Timmerman	Life Technologies Competes for Cheap DNA Sequencing In the race to cheaper gene sequencing.
The Motley Fool August 7, 2006 Stephen D. Simpson	Affymetrix: Price Always Matters Affymetrix has legit technology, but that doesn't mean it has infinite value for investors.
The Motley Fool September 8, 2006 Anders Bylund	National Semi Chooses Margins Over Volume National Semiconductor reported steady-as-she-goes earnings last night, with 9.6% revenue growth and a 46% boost in earnings per share over last year, despite this being the first quarter of reporting stock-based compensation.
The Motley Fool April 27, 2007 Brian Orelli	Making Money Off Your Competitors Affymetrix is looking appealing with a few new products and potential revenues from an unlikely source. Investors, take note.
The Motley Fool September 12, 2008 Brian Orelli	Monsanto Makes Half a Discovery Monsanto announces that it has sequenced the DNA of one of its "top-performing elite" lines of corn.
Reason August 2002 Charles Paul Freund	DNA Dough-Re-Mi A pretty girl may be like a melody, but the music of her DNA could have biotech companies whistling all the way to the bank. An executive at Maxygen, a California biotech firm, has suggested that if DNA sequences were converted to digital music they could be copyrighted as works of art.
Chemistry World January 27, 2012 Sarah Houlton	Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach.
The Motley Fool January 11, 2008 Brian Orelli	Biochip Packaging: Some Settling May Occur Biochip maker Illumina settles its disputes about patents with Affymetrix.
The Motley Fool July 26, 2007 Brian Orelli	Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit.
The Motley Fool August 16, 2007 Brian Orelli	More Drugmaker Growth Without the FDA All that high-tech lab equipment has to come from somewhere. Here's how investors can benefit from it, too.
Chemistry World July 13, 2011 Hayley Birch	Naked mole-rat genome holds clue to beating cancer The recently published draft sequence of the naked mole-rat genome promises to reveal the secrets of its long and remarkably cancer-free existence, potentially providing new targets for anti-cancer drugs.
IEEE Spectrum July 2010 Prachi Patel	Computing the Neanderthal Genome New software helped decode the DNA of our stone-age cousins
The Motley Fool June 19, 2006 Jim Mueller	Foolish Forecast: Sonic Stops Sliding Sales Piper Jaffray recently downgraded this stock, but management has reaffirmed its guidance. Here's what investors might expect following the burger purveyor's earnings announcement.
The Motley Fool September 27, 2006 Anders Bylund	Red Hat Disappoints. Or Does It? The open-source veteran is finding out the hard way that some income statements can be tricky. Investors, take note.
Reactive Reports Apr/May 2005 David Bradley	At Last, the Structure of DNA Researchers have made a significant advance in our understanding of life's main molecule, using X-ray crystallography to determine the three-dimensional structures of nearly all the possible sequences of a macromolecule.
The Motley Fool March 30, 2007 Ralph Casale	Another Genetic Sequencer Gobbled Up Roche buys out second-generation sequencer 454 Life Sciences. Investors, take note.
BusinessWeek February 20, 2006 Gene G. Marcial	Fast Growth At Illumina Is In The Genes The company has become a rising star in the complex analysis of gene variation, and the stock shows it.
InternetNews January 27, 2005 Susan Kuchinskas	Servers, Windows Help Microsoft Beat the Street Microsoft continues its growth, thanks to strong sales of its core products.
The Motley Fool October 24, 2007	Illumina Shines: Fool by Numbers The genetic research tech provider released third-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool March 18, 2008 Brian Orelli	The Nuts and Bolts of Drug Research Merck just released a pair of papers detailing the network of proteins that are linked to obesity, but the pharmaceutical company won't benefit much financially from its studies. So who will?
PC Magazine July 13, 2005 John R. Quain	DNA Printing Press A group of scientists believes it has an inexpensive nanoprinting technique that could lead to the mass production of DNA-based chips that could revolutionize disease detection.
Bio-IT World July 14, 2004 Malorye A. Branca	The Maven of Microarrays Affymetrix Research Institute's CEO, Stephen Fodor, discusses building a tech business without a blueprint
The Motley Fool January 23, 2004 Bill Mann	Mighty Microsoft Microsoft's earnings dropped 17%. Worried? Don't be, as the change was largely due to Microsoft switching from granting its employees stock options to granting them restricted stock, which is accounted for differently.